Biopol Chemicals (BIOPOL)

Score breakdown: P/E: 1/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Let me start with what I can verify. Biopol Chemicals is a ₹103 Cr market cap specialty chemical company, but the crucial numbers are either missing or alarming. The latest quarter shows sales of ₹0 Cr and net profit of ₹0 Cr. A business that currently earns nothing cannot be valued with a P/E of 23.81—that multiple is meaningless unless the next quarter brings real earnings. Graham taught me to treat numbers with suspicion when they are incomplete. Here book value, ROE, and debt/equity are absent, so I cannot measure a margin of safety. The Piotroski F-Score of 3/9 reinforces my caution; it says the financial position has deteriorated. The one bright spot is ROCE of 38.18%, which would be remarkable if it came from sustainable operations. But with zero current sales, I wonder whether that return is historical, one-time, or based on a very small equity base. Promoter holding of 65.81% is encouraging—owners have skin in the game—but high ownership is not the same as a durable moat. This is not a fast grower or a stalwart; it is a business in need of proof. Until I see a quarter with real sales and profits, a clear debt profile, and honest book value, I cannot pay ₹109.95. In Graham's language, this is speculation, not investment. I would put it on the watchlist, not in the portfolio. If Biopol can show that the zero quarter was unusual and that cash generation has returned, my view might change. But in investing, you do not fix a broken story with hope; you need figures. Here the figures fail the test.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer